Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

Verkoop
 Koop

VirBiotechnology live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Tommy Yap 2025 Feb 22, 16:00

Week Ahead: Australia Inflation and US Core PCE Price Index in Focus

Forex Indices
Why did stock market drop today due to Walmart's economic outlook.
Vanessa L 2025 Feb 21, 06:40

Why Did Stock Market Drop Today? Walmart’s Forecast Sparks Economic Concerns

Frances Wang 2025 Feb 20, 16:00

Shiba inu news: What is happening to Shiba Inu today?

Cryptocurrencies
Alvaro Ramos 2025 Feb 20, 16:00

Dow jones stock markets today: Dow falls 450 points

Indices
Frances Wang 2025 Feb 20, 16:00

Lucid stock news today: Is Lucid stock expected to go up?

Stocks
Frances Wang 2025 Feb 20, 16:00

Forex market update: US Dollar struggles on mixed data

Forex
Tommy Yap 2025 Feb 20, 16:00

Morning Note: Oil Prices Climb, UK Retail Sales Rise & U.S. PMI

Morning Note Oil
Space.Xia 2025 Feb 20, 16:00

Asian Markets Stagnate on Trade Fears; Alibaba Drives HK Surge

Info

Spread

0.07

Spread (%)

0.7330 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Maandag

14:31 - 20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1317980416

Uitstaande aandelen

137720000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.93

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot
Live Chat